METASTATIC COLORECTAL CANCER (MCRC)
Clinical trials for METASTATIC COLORECTAL CANCER (MCRC) explained in plain language.
Never miss a new study
Get alerted when new METASTATIC COLORECTAL CANCER (MCRC) trials appear
Sign up with your email to follow new studies for METASTATIC COLORECTAL CANCER (MCRC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for hard-to-treat colon cancer: experimental drug combo enters human trials
Disease control Not yet recruitingThis study tests an experimental drug (LPM6690176) combined with standard chemotherapy and bevacizumab in people with metastatic colorectal cancer that has a RAS mutation. The goal is to find a safe dose and see if the combination works better than standard treatment alone. About…
Matched conditions: METASTATIC COLORECTAL CANCER (MCRC)
Phase: PHASE1, PHASE2 • Sponsor: Luye Pharma Group Ltd. • Aim: Disease control
Last updated May 11, 2026 20:47 UTC
-
New drug duo targets hard-to-treat HER2 cancers in groundbreaking trial
Disease control Not yet recruitingThis study tests two drugs, zanidatamab and tislelizumab, together with chemotherapy or radiation for people with HER2-positive gastrointestinal cancers like rectal, stomach, and colon cancer. About 70 adults will receive the treatment to see if it can shrink tumors before surger…
Matched conditions: METASTATIC COLORECTAL CANCER (MCRC)
Phase: PHASE2 • Sponsor: Tao Zhang • Aim: Disease control
Last updated May 01, 2026 15:58 UTC